Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis

Medical Hypotheses

Volumn 85, Issue 6, 2015, Pages 754-760

  Akerele, O A ^a   Cheema, S K ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; FATTY ACID;

ANTIATHEROGENIC PROPERTY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL MIGRATION; CELL STIMULATION; CHOLESTEROL HOMEOSTASIS; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; FATTY ACID OXIDATION; HEART PROTECTION; HOMEOSTASIS; HUMAN; LIPID COMPOSITION; LIPID DIET; LIPID STORAGE; LIPOGENESIS; MACROPHAGE; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; ACYLATION; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CHEMISTRY; EVIDENCE BASED MEDICINE; METABOLISM;

ACYLATION; ANIMALS; ATHEROSCLEROSIS; BIOMARKERS; EVIDENCE-BASED MEDICINE; FATTY ACIDS; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MICE, INBRED C57BL; MODELS, CARDIOVASCULAR;

EID: 84947444167     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.10.013     Document Type: Article

References (88)

1. Cockburn A., Barraco R.A., Reyman T.A., Peck W.H. Autopsy of an Egyptian mummy. Science 1975, 187:1155-1160.
2. Zimmerman M.R. The paleopathology of the cardiovascular system. Tex Heart Inst J 1993, 20:252-257.
3. Quiney J.R., Watts G.B. Introduction. Classic papers in hyperlipidemia 1989, Science Press Limited, London. J.R. Quiney, G.B. Watts (Eds.).
4. Konstantinov I.E., Mejevoi N., Anichkov N.M. Nikolai N. Anichkov and his theory of atherosclerosis. Tex Heart Inst J 2006, 33:417-423.
5. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006, 6:508-519.
6. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009, 27:165-197.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
8. Methe H., Weis M. Atherogenesis and inflammation-was Virchow right?. Nephrol Dial Transplant 2007, 22:1823-1827.
9. Chen C.H., Henry P.D. Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression. Proc Assoc Am Physicians 1997, 109:351-361.
10. Linares A., Perales S., Palomino-Morales R.J., Castillo M., Alejandre M.J. Nutritional control, gene regulation, and transformation of vascular smooth muscle cells in atherosclerosis. Cardiovasc Hematol Disord: Drug Targets 2006, 6:151-168.
11. Keele K.D. Leonardo Davinci on movement of the heart and blood 1952, Harvey and Blythe Ltd., London.
12. Getz G.S., Reardon C.A. Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol 2005, 26:242-249.
13. Hu F.B., Stampfer M.J., Manson J.E., et al. Dietary fat intake and the risk of coronary heart disease in women. New Engl J Med 1997, 337:1491-1499.
14. Ascherio A., Rimm E.B., Giovannucci E.L., Spiegelman D., Stampfer M., Willett W.C. Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States. Br Med J 1996, 313:84-90.
15. Maiolino G., Rossitto G., Caielli P., Bisogni V., Rossi G.P., Calò L.A. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. Mediators Inflamm 2013, 714653.
16. Wu R., Huang Y.H., Elinder L.S., Frostegård J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 1998, 18:626-630.
17. Schmitz G., Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis 2010, 208:10-18.
18. Aiyar N., Disa J., Ao Z., et al. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 2007, 295:113-120.
19. Lucas A., Grynberg A., Lacour B., Goirand F. Dietary n-3 polyunsaturated fatty acids and endothelium dysfunction induced by lysophosphatidylcholine in Syrian hamster aorta. Metabolism 2008, 57:233-240.
20. Matsumoto T., Kobayashi T., Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 2007, 14:3209-3220.
21. Rosenblat M., Vaya J., Shih D.M., Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 2005, 179:69-77.
22. Rozenberg O., Shih D.M., Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003, 23:461-467.
23. Masayuki M., Hirokazu H., Tetsuo A. The expression of extracellular-superoxide dismutase is increased by lysophosphatidylcholine in human monocytic U937 cells. Atherosclerosis 2002, 163:223-228.
24. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004, 37:1304-1316.
25. Hung N.D., Sok D.E., Kim M.R. Prevention of 1-palmitoyl lysophosphatidylcholine-induced inflammation by polyunsaturated acyl lysophosphatidylcholine. Inflamm Res 2012, 61:473-483.
26. Browning L.M., Walker C.G., Mander A.P., et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012, 96:748-758.
27. Ottestad I., Hassani S., Borge G.I., et al. Fish oil supplementation alters the plasma lipidomic profile and increases long-chain PUFAs of phospholipids and triglycerides in healthy subjects. PLoS ONE 2012, 7:e42550.
28. Balogun K.A., Albert C.J., Ford D.A., Brown R.J., Cheema S.K. Dietary omega-3 polyunsaturated fatty acids alter the fatty acid composition of hepatic and plasma bioactive lipids in C57BL/6 mice: a lipidomic approach. PLoS ONE 2013, 21:e82399.
29. Balogun K.A., Randunu R.S., Cheema S.K. The effect of dietary omega-3 polyunsaturated fatty acids on plasma lipids and lipoproteins of C57BL/6 mice is age and sex specific. Prostaglandins Leukot Essent Fatty Acids 2014, 91:39-47.
30. Magee R. Arterial disease in antiquity. Med J Australia 1998, 169:663-666.
31. Faxon D.P., Creager M.A., Smith S.C., et al. Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American heart association. Circulation 2004, 109:2595-2604.
32. Heart and Stroke Foundation of Canada, 2015. www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm.
33. Toth P.P. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008, 62:1246-1254.
34. Napoli C., D'armiento F.P., Mancini F.P., et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997, 100:2680-2690.
35. Berg J.M., Tymoczko J.L., Stryer L. Biochemistry 2002, W H Freeman, New York. 5th ed.
36. Ohtani H., Hayashi K., Hirata Y., et al. Effects of dietary cholesterol and fatty acids on plasma cholesterol level and hepatic lipoprotein metabolism. J Lipid Res 1990, 31:1413-1422.
37. Califf R.M., Wagner G.S. Acute coronary care: principles and practice 2012, Springer science and business media, p. 33-35.
38. Carson J.A., Burke F.M., Hark L. Cardiovascular nutrition: disease management and prevention 2004, American Dietetic Association, Medical, p. 33-34.
39. Kita T., Kume N., Yokode M., et al. Oxidized-LDL and atherosclerosis. Role of LOX-1. Ann N Y Acad Sci 2000, 902:95-100.
40. Johnsen S.H., Fosse E., Joakimsen O., et al. Monocyte count is a predictor of novel plaque formation: a 7-year follow-up study of 2610 persons without carotid plaque at baseline the Tromsø Study. Stroke 2005, 36:715-719.
41. Østerud B., Bjørklid E. Role of monocytes in atherogenesis. Physiol Rev 2003, 83:1069-1112.
42. Fuhrman B., Partoush A., Volkova N., Aviram M. Ox-LDL induces monocyte-to-macrophage differentiation in vivo: possible role for the macrophage colony stimulating factor receptor (M-CSF-R). Atherosclerosis 2008, 196:598-607.
43. Rizzo M., Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006, 99:1-14.
44. Dowhan W. Molecular basis for membrane phospholipid diversity: why are there so many lipids?. Annu Rev Biochem 1997, 66:199-232.
45. Sato H., Kato R., Isogai Y., et al. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008, 283:33483-33497.
46. Hill E.E., Lands W.E.M. Phospholipid metabolism. Lipid metabolism 1970, 185-277. Academic press, London, New York. S.J. Wakil (Ed.).
47. Munder P.G., Modolell M., Andreesen R., Weltzien H.U., Westphal O. Lysophosphatidylcholine (lysolecithin) and its synthetic analogues. Immunemodulating and other biologic effects. Springer Semin Immunopathol 1979, 203:187-203.
48. Santamarina-Fojo S., Gonzalez-Navarro H., Freeman L., Wagner E., Nong Z. Hepatic lipase, lipoprotein metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2004, 24:1750-1754.
49. Gauster M., Rechberger G., Sovic A., et al. Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine. J Lipid Res 2005, 46:1517-1525.
50. Glomset J.A. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophys Acta 1962, 65:128-135.
51. Wells I.C., Peitzmeier G., Vincent J.K. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol 1986, 45:303-310.
52. Xie Y., Meier K.E. Lysophospholipase D and its role in LPA production. Cell Signal 2004, 16:975-981.
53. Chen L., Liang B., Froese D.E., et al. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 1997, 38:546-553.
54. Park C.H., Kim M.R., Han J.M., Jeong T.S., Sok D.E. Lysophosphatidylcholine exhibits selective cytotoxicity, accompanied by ROS formation, in raw 264.7 macrophages. Lipids 2009, 44:425-435.
55. Watanabe T., Pakala R., Koba S., Katagiri T., Benedict C.R. Lysophosphatidylcholine and reactive oxygen species mediate the synergistic effect of mildly oxidized LDL with serotonin on vascular smooth muscle cell proliferation. Circulation 2001, 103:1440-1445.
56. Afrimzon E., Zurgil N., Shafran Y., Leibovich P., Sobolev M., Guejes L., et al. The use of sequential staining for detection of heterogeneous intracellular response of individual Jurkat cells to lysophosphatidylcholine. J Immunol Methods 2013, 387:96-106.
57. McMurray H.F., Parthasarathy S., Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest 1993, 92:1004-1008.
58. Yang X., Cai B., Sciacca R.R., Cannon P.J. Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res 1994, 74:318-328.
59. Carneiro A.B., Iaciura B.M., Nohara L.L., et al. Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-κB translocation and MAPK/ERK phosphorylation. PLoS ONE 2013, 30:e76233.
60. Quinn M.T., Parthasarathy S., Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1998, 85:2805-2809.
61. Liu-Wu Y., Hurt-Camejo E., Wiklund O. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis 1998, 137:351-357.
62. Han K.H., Hong K.H., Ko J., et al. Lysophosphatidylcholine up-regulates CXCR4 chemokine receptor expression in human CD4 T cells. J Leukoc Biol 2004, 76:195-202.
63. Oestvang J., Anthonsen M.w., Johansen B. Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release. FEBS Lett 2003, 555:257-262.
64. Wong J.T., Tran K., Pierce G.N., Chan A.C., O K., Choy P.C. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J Biol Chem 1998, 273:6830-68336.
65. Hsieh C.C., Yen M.H., Liu H.W., Lau Y.T. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 2000, 151:481-491.
66. Carpenter K.L., Dennis I.F., Challis I.R., et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 2001, 505:357-363.
67. Takahashi M., Okazaki H., Ogata Y., Takeuchi K., Ikeda U., Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 2002, 161:387-394.
68. Zurgil N., Afrimzon E., Shafran Y., et al. Lymphocyte resistance to lysophosphatidylcholine mediated apoptosis in atherosclerosis. Atherosclerosis 2007, 190:73-83.
69. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997, 272:20963-20966.
70. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
71. Watanabe M., Okada T. Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. Mol Cell Biochem 2003, 248:209-215.
72. Rabini R.A., Galassi R., Fumelli P., et al. Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 1994, 4:915-919.
73. Pietilainen K.H., Sysi-Aho M., Rissanen A., et al. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS ONE 2007, 2:e218.
74. Leaf A., Xiao Y.F., Kang J.X., Billman G.E. Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias. J Membr Biol 2005, 206:129-139.
75. Hulbert A.J., Turner N., Storlien L.H., Else P.L. Dietary fats and membrane function: implications for metabolism and disease. Biol Rev Camb Philos Soc 2005, 80:155-169.
76. Stillwell W., Wassall S.R. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003, 126:1-27.
77. Hayashi K., Takahashi M., Nishida W., et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ Res 2001, 89:251-258.
78. Yoshida K., Nishida W., Hayashi K., et al. Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo. Circulation 2003, 108:1746-1752.
79. Block R.C., Duff R., Lawrence P., et al. The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin. Prostaglandins Leukot Essent Fatty Acids 2010, 82:87-95.
80. Sekas G., Patton G.M., Lincoln E.C., Robins S.J. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J Lab Clin Med 1985, 105:190-194.
81. Baisted D.J., Robinson B.S., Vance D.E. Albumin stimulates the release of lysophosphatidylcholine from cultured rat hepatocyte. Biochem J 1988, 253:693-701.
82. Brindley D.N. Hepatic secretion of lysophosphatidylcholine: a novel transport system for polyunsaturated fatty acids and choline. J Nutr Biochem 1993, 4:442-449.
83. Plückthun A., Dennis E.A. Acyl and phosphoryl migration in lysophospholipids: importance in phospholipid synthesis and phospholipase specificity. Biochem 1982, 21:1743-1750.
84. Croset M., Brossard N., Polette A., Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 2000, 345:61-67.
85. Hung N.D., Kim M.R., Sok D.E. Mechanisms for anti-inflammatory effects of 1-[15(s)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan a-induced peritonitis. Br J Pharmacol 2011, 162:1119-1135.
86. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006, 281:7649-7656.
87. Hara S., Shike T., Takasu N., Mizui T. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler Thromb Vasc Biol 1997, 17:1258-1266.
88. Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. Eur Heart J 2005, (Supplement F):F4-F7.